New research reveals that people who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who stop traditional lifestyle programs.
Published data in a prominent health publication demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Users purchasing such drugs need to be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting mass within about a year and a half.
Weighing Approaches
The study, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with conventional dieting.
The team point out that people who shed pounds through diet and exercise typically experience a less rapid weight regain—around 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Experts propose the way of the drugs explains the amplified regain.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication means appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
Health authorities advise the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the likelihood of weight regain, the treatment should be considered life-long.
This perspective is echoed by drug manufacturers, who say that the results "emphasize the persistent character of obesity," comparing it to managing conditions like high blood pressure.
Patient Testimonies
People who have stopped the medication report a sudden resurgence of cravings.
"It was like something flipping and I was suddenly ravenous," described one woman.
The struggle is compounded if patients have not developed lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is greater among females than men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone cure and long-term success likely depends on ongoing lifestyle management.
